Company: BGLC
Filing Date: 2025-05-15
Form Type: 10-Q
Source: 0001477932-25-003821
Chunk: 29

Company: BioNexus Gene Lab Corp
Filing Date: 2025-05-15
Form: 10-Q
Item: Part I, Item 1
Chunk 29
---
792,176)  -   (1,793,582)                 GROSS PROFIT  1,662   341,831   -   343,493                  OTHER INCOME                Dividend income   -   8,934   -   8,934 Interest income  20,002   3,566   -   23,568 Fair value gain on investments in equity securities  -   4,514   -   4,514 Reversal of expected credit losses  -   25,153   -   25,153 Others  3,893   25,358   -   29,251 TOTAL OTHER INCOME  23,895   67,525   -   91,420                  OPERATING EXPENSES                Sales and marketing  (27,640)  (508,990)  (4,065)  (540,695)Research and development  (12,139)  -   -   (12,139)General and administrative  (56,006)  (125,133)  (210,737)  (391,876)Fair value loss on investments in equity securities  -   (68,497)  -   (68,497)Provision for expected credit losses   -   (40,124)  -   (40,124)TOTAL OPERATING EXPENSES  (95,785)  (742,744)  (214,802)  (1,053,331)                 LOSS FROM OPERATIONS  (70,228)  (333,388)  (214,802)  (618,418)                 FINANCE COSTS  (3,364)  (1,502)  (43)  (4,909)                 LOSS BEFORE TAX  (73,592)  (334,890)  (214,845)  (623,327)                 NET LOSS ATTRIBUTABLE TO COMMON SHAREHOLDERS  $(73,592) $(334,890) $(214,845) $(623,327)